Evidence map›Paper›PMID 41282189›Full record

ArticleResearch square2025

NMR assignments of the human homodimeric mitochondrial ATP synthase inhibitor IF1.

Julia Jerolamon-Martínez, Nathan Alder, Andrei Alexandrescu

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Julia Jerolamon-MartínezUniversity of Connecticut.
Nathan AlderUniversity of Connecticut.
Andrei AlexandrescuUniversity of Connecticut.

Funding

First-in-class peptide therapeutics for mitochondrial disorders: molecular mechanism of action and optimization of designR01AG065879 · NIA · UNIVERSITY OF CONNECTICUT STORRS · PI ALDER, NATHAN N · 2020 to 2024
$2.6M
An Open-access 800 MHz NMR Spectrometer for Central New EnglandS10RR023041 · NCRR · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI HOCH, JEFFREY C · 2007 to 2007
$2.0M
An Open-access 700 MHz NMR Spectrometer for Central New EnglandS10OD034297 · OD · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI HOCH, JEFFREY C · 2023 to 2023
$2.0M
NCRR NIH HHS S10 RR023041NIA NIH HHS R01 AG065879NIH HHS S10 OD034297
6 · The paper itself

Abstract

ATPase inhibitory factor 1 (IF1) is the only known endogenous, proteinaceous inhibitor of mitochondrial ATP synthase in mammals. The inhibitor forms an antiparallel coiled-coil, which binds ATP synthase through an N-terminal a-helix extension that is disordered in the free protein. Because the IF1 dimer affects mitochondrial bioenergetics through its modulation of ATP synthase, it is a therapeutic target for cancer and cardiac disease. Here, we report

Indexed as

ATPase inhibitorATP synthasecoiled-coil dimermitochondriapH-dependent oligomer

Identifiers

PMID41282189
PMCPMC12637840

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.